Gene therapy, Born Blind
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...
One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.
At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal ...
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results